<DOC>
	<DOC>NCT02448095</DOC>
	<brief_summary>This observational study aims at assessing the tolerability and safety profiles of Ponatinib, a drug used for Chronic Myeloid Leukemia patients who are Philadelphia positive. This drug is used during the chronic phase of the disease, according to the Italian national compassionate law 648/96.</brief_summary>
	<brief_title>Retrospective Evaluation of CML Patients in the National Compassionate Program</brief_title>
	<detailed_description>This observational study aims at assessing the tolerability and safety profiles of Ponatinib, a drug used for Chronic Myeloid Leukemia patients who are Philadelphia positive. This drug is used during the chronic phase of the disease, according to the Italian national compassionate law 648/96.</detailed_description>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Ponatinib</mesh_term>
	<criteria>CML Ph+ patients in chronic phase 18 years old or older Patients have received either Dasatinib or Nilotinib and resulted resistant or not tolerant to the drugs or have developed the T3151 mutation Patients have started Ponatinib at least 12 months before registration Informed consent signed at registration CML Ph+ patients in accelerated or blast phase with acute lymphoblastic leukemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chronic myeloid leukemia</keyword>
	<keyword>Philadelphia positive</keyword>
	<keyword>Compassionate use</keyword>
</DOC>